Background-The development of a reproducible, sensitive, and standardised human papillomavirus (HPV) polymerase chain reaction (PCR) test is required to implement HPV testing in cervical cancer screening programmes and for triaging women with mild to moderate dysplasia. Aims-To determine the intermethod agreement between diVerent GP5+/6+ and MY09/11 PCR based protocols for the detection and typing of high risk (HR) HPV DNA in cervical smears and to assess the intramethod reproducibility of the GP5+/6+ PCR enzyme immunoassay (EIA) for HR-HPV detection. Worldwide, cervical cancer is one of the most common forms of cancer among women. Although cytomorphological screening of cervical smears (the Papanicolaou test) has reduced the incidence of cervical cancer significantly, the test still has some limitations with respect to sensitivity and specificity. False negative rates for cervical premalignant lesions and cervical cancer between 15% and 50% and false positive rates of about 30% have been reported.
Worldwide, cervical cancer is one of the most common forms of cancer among women. Although cytomorphological screening of cervical smears (the Papanicolaou test) has reduced the incidence of cervical cancer significantly, the test still has some limitations with respect to sensitivity and specificity. False negative rates for cervical premalignant lesions and cervical cancer between 15% and 50% and false positive rates of about 30% have been reported. [1] [2] [3] To date, it has been shown that high risk human papillomavirus (HR-HPV) genotypes are implicated in the aetiology of cervical cancer. 4 Consequently, the inclusion of HR-HPV testing in cervical cancer screening programmes and the triaging of women with mild to moderate cervical dysplasia has been advocated. [5] [6] [7] [8] As HPV cannot be cultured in vitro and no suitable serological assays are at present available, current methods are based on the detection of HPV DNA in exfoliated cervical cells. These methods include the hybrid capture assay (HCA), a simple direct HPV DNA detection assay using signal amplification, 9 and the polymerase chain reaction (PCR) which is based on the in vitro amplification of target sequences. 10 Both approaches seem robust and potentially suitable for routine. Concerning the PCR based methods, HPV type specific PCR are not suitable for large clinical trials owing to the wide variety of HPV genotypes infecting the genital tract. Broad spectrum detection has therefore been facilitated by consensus PCR assays, with general primers selected from highly conserved sequences of the majority of mucosal HPV genotypes. [11] [12] [13] [14] Moreover, subsequent detection steps are continuously amenable to modifica-tions to render these general primer PCR assays more feasible for large numbers of samples.
In order to consider HPV testing for cervical cancer screening programmes, issues like the reproducibility between diVerent HPV methods and between diVerent testing centres need further attention. The reproducibility of both HCA and the widely used general primer MY09/11 mediated PCR assay using diVerent read-out protocols has already been evaluated. [15] [16] [17] Recently, the read-out system of another widely used general primer mediated PCR system, the GP5+/6+ PCR, has been converted from conventional radioactive Southern blot hybridisation of the PCR products in a colorimetric enzyme immunoassay (EIA) (GP5+/6+ PCR-EIA). 18 Like the latest version of HCA, 19 it is a nonradioactive detection procedure in microtitre plate format which is easy to perform and generates objective numerical data. Although this new GP5+/6+ PCR-EIA system has already been evaluated on clinical specimens, 20 no interlaboratory reproducibility rates are yet available. We therefore assessed the reproducibility of the GP5+/6+ PCR-EIA in a multicentre intermethod and intramethod evaluation. The results of these evaluations are presented in this paper.
Methods

SELECTION OF REFERENCE SAMPLES AND COMPOSITION OF TEST PANELS
Cervical smears were selected from a group of women with abnormal cervical cytology (> mild dysplasia) attending the outpatient clinics of the University Hospital Vrije Universiteit in Amsterdam, The Netherlands. The cervical smears were pretreated as described before. 10 Selection of study samples was based on the following criteria: (1) One laboratory served as the reference laboratory (A) and established the test panel of cervical smears. Aliquots of these specimens (50 µl) were coded and distributed by laboratory A to diVerent laboratories. In the test panels, the HPV negative samples were randomly divided between the HPV positive samples; 10 µl of the study samples had to be used for HPV testing. All participating laboratories had experience with HPV PCR technology. The reference laboratory did not participate in the HPV testing but collected and compared the HPV PCR test results from the diVerent laboratories with its own reference data. The GP5+/6+ PCR-EIA results from the reference laboratory (A) were used as the gold standard as these results were confirmed by an alternative HPV E7 TS-PCR system and were therefore considered conclusive.
INTERMETHOD COMPARISON
Four laboratories (B to E) participated in the intermethod evaluation for the detection and typing of HR-HPV in cervical smears. These four laboratories applied their own in-house HPV PCR assays.
One of these laboratories (B) used the same method as the reference laboratory (A)-that is, GP5+/6+ PCR-EIA with a high risk oligo cocktail probe for the detection of HR-HPV and individual oligo probes for HPV typing and was provided with standardised protocols after an extensive training period.
Another laboratory (C) applied the GP5+/6+ PCR followed by agarose gel electrophoresis to detect the presence of HPV DNA and used type specific (TS) PCR for HPV 6, 11, 16, and 18 combined with direct sequence analysis of GP5+/6+ PCR products in cases of GP5+/6+ PCR positive and TS-PCR negative samples for HPV typing.
Two other laboratories (D and E) used MY09/11 primer mediated PCR. The presence of HPV DNA was analysed by agarose gel electrophoresis of the MY09/11 generated PCR products while typing was performed by restriction fragment length polymorphism (RFLP) analysis and hybridisation of the RFLP products with a generic oligonucleotide probe mixture.
INTRAMETHOD COMPARISON
For the intramethod comparison, four other laboratories (F to I) without previous experience with GP5+/6+ PCR-EIA participated in the studies. The reference laboratory (A) provided a standard operating procedure, digoxigenin labelled high risk oligo cocktail probes, and the GP5+/bioGP6+ primers. The quality of this material was first validated and a sensitivity of between 10 and 200 copies of the HPV genome, depending on the HPV type, could be attained. 17 Other reagents and equip-ment had to be purchased from their local distributors.
STATISTICAL ANALYSIS
The intermethod and intramethod agreement for HR-HPV detection was assessed by pairwise comparison of the test results with the reference data using percentage of agreement and the kappa ( ) statistic. Values express the proportion of possible agreement beyond chance. A estimate of less than 0.4 represents poor agreement, a estimate between 0.4 and 0.75 is fair to good agreement, and a estimate of more than 0.75 is excellent agreement. 23 For HPV typing, the intermethod agreement was assessed by pairwise comparison of the typing results with the reference data by the percentages of agreement. The 2 test was used to indicate significant diVerences between typing of single and multiple HPV infections.
Results
INTERMETHOD COMPARISON BETWEEN GP5+/6+ AND MY09/11 PCR BASED PROTOCOLS
HPV detection analysis on cervical smears
Aliquots of 20 well characterised cervical smears were subjected to diVerent PCR protocols employed in the diVerent laboratories and compared with the reference data ( Evaluation of the single HPV infections showed that laboratory B identified the correct HPV type in all the six samples (samples 6 to 11). However, in two samples (sample 6 and 11) an additional HR-HPV type was detected compared with the reference data. Laboratory C detected the correct HR-HPV type in four of the six single HPV infections (samples 6, 9, 10, and 11). In one single HPV infection (sample 8) the HR-HPV type (HPV 51) could not be identified, while the remaining sample (sample 7) was tested HPV DNA negative. Only laboratory D identified the correct HPV type in all the six single HPV infections (samples 6 to 11) whereas laboratory E correctly identified the HR-HPV type in four of the six single HPV infections (samples 6, 9, 10, and 11). The two remaining samples (samples 7 and 8) were tested HPV DNA negative.
Evaluation of the multiple HPV infections showed that laboratory B correctly typed the HR-HPVs present in all the nine samples (samples 12 to 20). However, in two samples (samples 16 and 18) an additional HR-HPV type was detected compared with the reference data. Only a single HPV type was detected in all nine multiple HPV infections by laboratory C. In all these nine cases the HR-HPV type detected corresponded with one of the multiple HPV types present in the sample according to the reference data. Laboratory D detected single HPV types in five of the nine multiple HPV infections. In three of these (samples 14, 15, Taking the typing data together, the percentages of overall agreement with the reference laboratory were 100%, 48%, 48%, and 32% for the methods employed in laboratories B, C, D, and E, respectively. Moreover, the typing agreement of all laboratories together was significantly higher (p < 0.001) for single HPV infections (83%; 20/24) than for multiple HPV infections (49%; 37/76).
INTRAMETHOD COMPARISON OF HR-HPV GP5+/6+
PCR-EIA Crude cell suspensions of 50 cervical smears were analysed in diVerent laboratories by GP5+/6+ PCR-EIA and compared to the reference data.
As shown in table 3, among the HPV negative samples, one sample (3) was tested HR-HPV positive by laboratory I only. Among the HR-HPV positive samples, four samples (24, 27, 41 , and 47) were tested false negative. One of these samples (47) was tested HR-HPV negative by two independent laboratories (H and I), while the remaining three samples were scored HR-HPV negative by only one of the laboratories.
Laboratory 
Discussion
In view of potential applications of HR-HPV PCR assays in cervical cancer screening programmes, 24 the intermethod agreement of GP5+/6+ and MY09/11 consensus PCR based protocols was investigated by multiple test centres. A higher reproducibility for HR-HPV detection than for HPV typing was found. Among the diVerent protocols, GP5+/6+ PCR amplification followed by hybridisation of the PCR products with a cocktail probe for HR-HPV types in an EIA format revealed the highest agreement with the reference data. Moreover, excellent intramethod agreement between other test centres was obtained with this method in a subsequent study. These data indicate that HR-HPV GP5+/6+ PCR-EIA has outstanding reproducibility.
INTERMETHOD COMPARISON
Comparison of diVerent in-house HPV PCR methods with the reference data showed that the agreement was fair to excellent ( values: 0.5 to 1) for the detection of HR-HPV DNA in cervical smears (table 1) . A markedly lower agreement rate (75%) for HPV detection was observed for laboratory E using MY09/11 PCR and agarose gel analysis compared with other laboratories (90% to 100%). It has to be noted that the quality of the DNA in all samples was appropriate for eYcient PCR amplification of at least 500 base pair fragments. As the MY09/11 PCR amplifies a shorter fragment of 450 base pairs in the HPV L1 open reading frame, the disagreement cannot simply be explained by inadequate DNA quality of the specimens. This is further supported by the observation that laboratory D, using the same MY9/11 PCR assay including the read-out protocol, obtained an excellent agreement (95%) with the reference data for the detection of HPV DNA. In addition, the agreement between both laboratories (D and E) using MY09/11 PCR was only fair ( value: 0.40). The discrepancies were restricted to false negative test results. Moreover, since all HPV positive samples included in the test panel contained high amounts of HPV DNA according to the optical density values of the reference data, the false negative test results are also unlikely to be a result of sampling errors. Furthermore, a broader range in agreement was found for HPV typing compared with the detection of HPV DNA. Moreover, the HPV typing results varied more strongly for the multiple infections compared with the single infections (p < 0.001; table 2). In our study it was shown that diVerences in read-out systems make a large contribution to variations in HPV typing. Direct sequencing of GP5+/6+ PCR products apparently failed to identify underrepresented HPV types in the multiple HPV infections, in contrast to hybridisation of GP5+/6+PCR products with digoxigenin labelled oligo probes in EIA. In addition, this latter method detected some additional HPV types compared with the reference laboratory owing to diVerences in the interpretation of weak signals. That variations in HPV typing may occur using diVerent protocols is further substantiated by the observation that both laboratories using the same MY09/11 PCR-RFLP procedures had a lower detection rate for multiple HPV infections than the laboratory using GP5+/6+ PCR-EIA. However, in another study, 25 the reverse was found when a similar dot blot procedure was used for HPV typing of both GP5+/6+ and MY09/11 PCR products derived from the same series of samples. These data suggest that the eYciency of HPV testing by consensus PCR is not only dependent on the specificity of the primers but also on the read-out system applied. Moreover, these results strongly reinforce the need for standardisation of read-out systems employed in diVerent laboratories. 26 
INTRAMETHOD COMPARISON
In the intramethod comparison, the reproducibility of the HR-HPV GP5+/6+ PCR-EIAtested on 50 well characterised specimenswas fairly uniform among diVerent laboratories, as shown by the small diVerences in the agreement rates (92% to 100%; table 4). Except for one case, the few observed discrepancies comprised false negative test results of HPV positive samples (table 3) . Nevertheless, the five false negative test results among a total of 200 tests in the four laboratories show a high overall sensitivity of 97.5% (195/200). Likewise, the specificity of GP5+/6+ PCR for HR-HPV detection was excellent. There was only one single false positive test result obtained among the 200 tests conducted in the four laboratories, resulting in an overall specificity of 99.5% (199/200).
Finally, the main goal of this study was the recognition that HPV testing can be performed reliably by consensus HPV PCR based protocols and between diVerent testing centres. Smits et al already showed that agreement between CPI/II PCR and MY09/11 PCR for the detection of HPV DNA in cervical smears was excellent ( values between 0.82 and 0.84). 27 Moreover, high interlaboratory reproducibilities for the detection of HPV DNA with MY09/11 PCR in clinical specimens of about 88% to 97% have been found previously. 16 17 The results of our study are in line with these reports and suggest that the variation in HR-HPV detection by diVerent consensus HPV PCR based protocols can be quite small. Most importantly, however, testing for HR-HPV as a group appears to be more reproducible than testing for individual HPV types. Since results from recent case-control studies show that the risk for women of getting cervical cancer does not diVer significantly for the diVerent HPV genotypes, 28 29 individual HPV typing is unlikely to be more relevant clinically than HR-HPV group specific testing. With the data obtained in this study, this argues that HR-HPV group specific detection should be the strategy of choice in cervical cancer screening programmes. It has additionally been shown that the HR-HPV GP5+/6+ PCR-EIA has high reproducibility for the detection of HR-HPVs and can easily be transferred to other laboratories provided that standardised protocols and validated reagents are used. Therefore, this test could be used in large clinical trials. Recently, a trial of 44 000 women was started to evaluate HR-HPV testing with the GP5+/6+ PCR-EIA in population based cervical cancer screening.
